

- First author of “Stapedial reflex: a possible novel biomarker of early bulbar involvement in Amyotrophic Lateral Sclerosis patients”. *Audiology and Neurotology*. In press.
- Last author of “COVID-19 impact on neurology training program in Italy.” *Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. January 2021. doi:10.1007/s10072-020-04991-5
- First author of “Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail”. *Neurological Sciences*. October 2020. doi:10.1007/s10072-020-04783-x
- First author of “Plasma pNfH levels differentiate SBMA from ALS”. *Journal of Neurology, Neurosurgery and Psychiatry*. 2020;91(2). doi:10.1136/jnnp-2019-320624
- Co-author of “Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience”. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. September 2020:1-4. doi:10.1080/21678421.2020.1820043
- Co-author of “Validation of the Italian version of self-administered ALSFRS-R scale”. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. August 2020:1-3. doi:10.1080/21678421.2020.1813307
- Co-author of “Validation of the revised classification of cognitive and behavioural impairment in ALS”. *Journal of Neurology, Neurosurgery and Psychiatry*. 2019;90(7). doi:10.1136/jnnp-2018-319696
- Co-author of “Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort.” *J Neurol Neurosurg Psychiatry*. 2019;90(6):666-673. doi:10.1136/jnnp-2018-319611
- Co-author of “Use of poly(DL-lactide-ε-caprolactone) membranes and mesenchymal stem cells from the Wharton's jelly of the umbilical cord for promoting nerve regeneration in axonotmesis: in vitro and in vivo analysis”; *Differentiation*, 2012 Dec;84(5):355-65. doi: 10.1016/j.diff.2012.10.001. Epub 2012 Nov 7.
- Graduate thesis: “The immunosuppressive role of Alemtuzumab in multiple sclerosis therapy: immunological study lasted 2 years”.